Status:
COMPLETED
Combined Therapy for Cervical Disc Herniation
Lead Sponsor:
Nanchong Central Hospital
Conditions:
VAS and JOA Scores
Adverse Reaction Rates
Eligibility:
All Genders
30-80 years
Phase:
NA
Brief Summary
This study mainly explores the efficacy and safety of low-temperature plasma radiofrequency ablation combined with ozone injection and collagenase in the treatment of cervical disc herniation.The prim...
Detailed Description
1. Research Objective This study mainly explores the efficacy and safety of low-temperature plasma radiofrequency ablation combined with ozone injection and collagenase in the treatment of cervical di...
Eligibility Criteria
Inclusion
- Patients must be diagnosed with cervical disc herniation through MRI or CT, with single-level disc protrusion (C3-C7) that occupies ≤1/3 of the central spinal canal.
- Aged between 30 and 80 years.
- Have suffered from persistent neck/shoulder pain or upper extremity radiating pain for ≥3 months.
- The pain does not respond to conventional treatments, including traction, massage, and oral medications.
- Be willing to undergo surgery therapy.
- Have no prior cervical spine surgery.
Exclusion
- Cervical instability, myelopathic spondylosis, severe spinal stenosis (canal occupancy \>1/3), or ligament calcification.
- Severe osteoporosis (T-score \<-2.5).
- Extruded or sequestered disc herniation
- Coagulation disorders or active infections
- Cervical deformities, tumors, or a history of cervical spine surgery
Key Trial Info
Start Date :
June 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06995066
Start Date
June 1 2023
End Date
July 1 2024
Last Update
May 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanchong Central Hospital
Nanchong, Sichuan, China, 637000